Introduction
============

Melanoma is a highly malignant skin tumor caused by the excessive proliferation of atypical melanocytes and frequently occurs on the skin of the trunk and four limbs or in the mucosal layer close to the skin. The incidence of melanoma in the People's Republic of China is low; however, it has been increasing in the recent years. More than 90% of the melanoma cases involve the skin tissues.[@b1-ott-9-4969],[@b2-ott-9-4969] Primary anorectal melanoma is relatively less common compared to the melanoma of other body parts. In addition, metastases of malignant tumors to the breast tissue are uncommon; the patient in the present study represents the fifth case reported in the English literature.

Case report
===========

A 55-year-old woman was initially diagnosed with "mixed hemorrhoids" at the Shenyang Proctology Hospital (Liaoning, People's Republic of China) with complaints of intermittent blood in the stool with tenesmus for 1 month. She underwent surgical resection, and postoperative paraffin pathology confirmed anorectal melanoma. However, the patient refused radical surgery and other treatment options. After 9 months, the patient developed a local recurrence. She was admitted to the Department of Surgical Oncology of The First Affiliated Hospital of China Medical University. Colonoscopy showed a smooth mucosa with a polypoid bulge of \~1.0×0.8 cm in size, located 6 cm close to the anal verge, without any erosion, ulcer, hemorrhage, or necrosis ([Figure 1](#f1-ott-9-4969){ref-type="fig"}). Microscopic examination showed diffusely distributed, small, and relatively uniform tumor cells with oval-shaped, deviated nuclei and deep staining ([Figure 2A](#f2-ott-9-4969){ref-type="fig"}). The tumor cells resembled plasma cells, showing evidence of mitosis and less cytoplasm without clear pigmentation ([Figure 2B](#f2-ott-9-4969){ref-type="fig"}). The results of the immunohistochemistry analyses performed using specific markers to confirm small-cell melanoma were as follows: cytokeratin (pan, −), synaptophysin (−), chromogranin A (−), CD20 (−), Pax-5 (−), CD3 (−), CDX2 (−), CD15 (−), S-100 (+; [Figure 2C](#f2-ott-9-4969){ref-type="fig"}); vimentin (+; [Figure 2D](#f2-ott-9-4969){ref-type="fig"}), HMB-45 (+), Melan-A (+), CD56 (+), CD138 (−), CD38 (−), MUM1 (−), and a Ki67 index of \~60%. Thus, the tumor was confirmed as small-cell melanoma. The patient underwent abdominoperineal resection. There was no metastasis to the regional lymph nodes (zero of eleven nodes); however, a single stage IIIC nodular melanoma with the TNM classification pT4bN1bM0 was found in the drainage region of lymph nodes. The patient still refused chemotherapy and radiotherapy; however, 40 days after surgery, she received biological therapy consisting of dendritic cells combined with cytokine-induced killer cells.

A tumor was detected in the left breast via ultrasonography after 4 months of radical surgery. Breast ultrasonography showed a hypoechoic region in the outer upper quadrant of the left breast sized 1.46×1.26 cm^2^ ([Figure 3A](#f3-ott-9-4969){ref-type="fig"}). The mass had atypical characteristics and strip-shaped blood flow around the edges (Breast Imaging Reporting and Data System 4C; [Figure 3B](#f3-ott-9-4969){ref-type="fig"}). The pathological examination of the specimen obtained via fine needle aspiration biopsy using a hollow needle showed morphological findings consistent with anorectal melanoma ([Figure 4A](#f4-ott-9-4969){ref-type="fig"}). The immunohistochemistry results were as follows: cytokeratin (pan, −), vimentin (+; [Figure 4B](#f4-ott-9-4969){ref-type="fig"}); S-100 (+), Melan-A (+; [Figure 4C](#f4-ott-9-4969){ref-type="fig"}); HMB-45 (+; [Figure 4D](#f4-ott-9-4969){ref-type="fig"}); CD3 (T lymphocytes, +), CD20 (B lymphocytes, +), Pax-5 (B lymphocytes, +), chromogranin A (−), synaptophysin (−), CD138 (−), ER (−), Her2 (−), P63 (−), GATA-3 (−), and a Ki67 index of \~70%, which confirmed anorectal melanoma metastatic to the breast.

Discussion
==========

Anorectal melanoma frequently occurs near the dentate line. As the tumor is highly invasive and lymphatic vessels are abundant near the dentate line, local spread and distant metastases may occur in the early phase of the disease, with a 1.2% metastasis rate to the breast, resulting in a 5-year overall survival of \<20%.[@b3-ott-9-4969]--[@b6-ott-9-4969] In the present study, 30 cases of melanoma metastatic to the breast that were reported from 1995 to 2015, including the present case, were reviewed retrospectively.[@b7-ott-9-4969]--[@b23-ott-9-4969] The mean patient age was 54 years, and 87.1% of the patients were women. The most common primary sites of melanoma were the skin tissues of the trunk (28.6%, eight out of 28 patients) and head and face (28.6%, eight out of 28 patients). Including the patient reported in the present study, only five patients were previously reported to have anorectal melanomas metastatic to the breast. Two of the patients died 3 months after metastasis to the breast. The average survival time after metastasis was \>12.5 months.

In 1984, Lee[@b24-ott-9-4969] showed that melanoma cells expressed estrogen receptors; however, the role of estrogen in the metastases to the breast is presently controversial. An association was previously reported between metastasis of melanoma to the breast and menopausal status. Arora and Robinson[@b25-ott-9-4969] reported 15 patients with melanomas that metastasized to the breast, of which 93% were premenopausal. Another retrospective study involving 27 cases also reported that 70% of the patients were at the premenopausal stage.[@b6-ott-9-4969] The breast tissue of older patients is more fibrous, and the relatively poor blood supply makes the environment unfavorable for metastasis in these patients. Arora and Robinson[@b25-ott-9-4969] suggested a direct role for estrogen in facilitating metastatic spread.

The inhibition of antitumor immune responses in human beings is associated with metastatic melanoma.[@b26-ott-9-4969],[@b27-ott-9-4969] Jayaraman et al[@b28-ott-9-4969] found, in a mouse model of melanoma, that the number of Treg cells increased in the peripheral blood of mice with metastatic melanoma and that the inhibition of Treg induction could effectively prevent the proliferation of tumor cells. The interactions of tumor cells with the microenvironment and the immune system are significant in the infiltration and metastasis of melanoma. In the clinical setting ([Table 1](#t1-ott-9-4969){ref-type="table"}), the average time from the diagnosis of the primary tumor to its metastasis to the breast was 49.9 months. Frequently, the tumors were identified as single lesions sized 0.8--6.0 cm. Primary tumors mostly involve the outer upper quadrant, consistent with the predilection sites for breast cancer.[@b29-ott-9-4969] The therapeutic principle used for the treatment of melanoma metastatic to the breast tissue does not differ from that of melanoma metastatic to other sites.[@b30-ott-9-4969] The standard therapeutic approach remains surgery supplemented with radiotherapy, chemotherapy, immunotherapy, and other treatments. In the present study, the retrospective analysis showed that almost one-third of the patients received radical mastectomy after the metastasis of melanoma, whereas approximately half of them preferred radiotherapy and chemotherapy as adjuvant therapies for the treatment of metastases to the breast.

Most melanoma patients with metastases to the breast already have local spread and metastases to multiple other organs that commonly include the epithelial tissues, lungs, brain, and liver.[@b6-ott-9-4969],[@b31-ott-9-4969],[@b32-ott-9-4969] We identified six out of 16 patients (37.5%) with metastases to other tissues and organs in addition to the breast. Metastasis to the breast is an indicator of poor prognosis.[@b33-ott-9-4969] Ravdel et al[@b6-ott-9-4969] reported that the median survival time of 27 patients who had melanomas metastasized to the breast was 12.9 months. In the present study, we reviewed eight of 15 patients who died within 1 year after metastasis to the breast. The patient in the present study refused chemotherapy after metastasis to the breast. To date, she has been followed-up for 5 months with no considerable changes in her condition.

Conclusion
==========

Metastasis of tumors to the breast is a very rare phenomenon. The possibility of metastasis should be considered in the patients with a history of melanoma or other malignant tumors when masses are detected in the breast tissue. The patients with metastasis to the breast often demonstrate accompanying multiple metastases to other tissues and organs; therefore, a comprehensive examination and assessment of the conditions of the patients are necessary, as it might directly influence the prognostic assessment and the establishment of effective therapeutic approaches.
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![Endoscopic findings: proctoscopy revealed a mass at the anorectal junction.](ott-9-4969Fig1){#f1-ott-9-4969}

![Hematoxylin and eosin immunohistochemical staining findings for the primary tumors are shown.\
**Notes:** (**A**) Smaller tumor cells with a diffuse distribution are observed in the anal tumor; hematoxylin--eosin stain, ×100. (**B**) High magnification microscopy showing a tumor cell morphology similar to that of plasma cells. The nuclei displayed atypia and conspicuous mitotic activity. (**C**) Tumor cells showing positive staining for S-100; immunohistochemistry staining, ×100. (**D**) Tumor cells showing diffuse positive staining for vimentin; immunohistochemistry staining, ×100.](ott-9-4969Fig2){#f2-ott-9-4969}

![Breast ultrasonography images.\
**Notes:** (**A**) A hypoechoic region sized 1.46×1.26 cm is seen in the outer upper quadrant of the left breast. (**B**) The mass has atypical characteristics and strip-shaped blood flow around the edges (BI-RADS 4C).\
**Abbreviation:** BI-RADS, Breast Imaging Reporting and Data System.](ott-9-4969Fig3){#f3-ott-9-4969}

![Immunohistochemical staining findings for the metastatic tumors are shown.\
**Notes:** (**A**) Metastatic tumor in the left breast showing morphological findings consistent with those of the anorectal melanoma; immunohistochemistry staining, ×100. (**B**) Metastatic tumor cells showing positive staining for vimentin; immunohistochemistry staining, ×100. (**C**) Metastatic tumor cells showing positive staining for Melan-A; immunohistochemistry staining, ×100. (**D**) Metastatic tumor cells showing positive staining for Hmb45; immunohistochemistry staining, ×100. Scale bar, 100 μm.](ott-9-4969Fig4){#f4-ott-9-4969}

###### 

Data summary of the case series

  Case number   Sex   Age (years)   History             Primary surgery   Time to metastasis (months)   Other metastasis location                Site                                     Size (cm)   Management of breast lump   Adjuvant therapy after metastasis   Time interval between breast metastasis and death (months)   References
  ------------- ----- ------------- ------------------- ----------------- ----------------------------- ---------------------------------------- ---------------------------------------- ----------- --------------------------- ----------------------------------- ------------------------------------------------------------ -------------------
  1             F     55            Anorectal           RR                13                            NF                                       Left upper outer                         1.5         NP                          Biotherapy                          \>5                                                          This case
  2             F     43            Conjunctiva         LE                24                            Nasopharynx, oropharynx                  Left                                     2           LE                          Chemotherapy                        4                                                            [@b8-ott-9-4969]
  3             F     78            Nasal cavity        NP                1                             NF                                       Left upper                               4           RR                          NP                                  8                                                            [@b9-ott-9-4969]
  4             F     69            Infraorbital area   RR                204                           Adrenal gland, anocelia, axilla          Left lower inner and right upper outer   2.3; 1.8    NP                          Chemotherapy                        NA                                                           [@b10-ott-9-4969]
  5             F     58            Chest wall          RR                96                            NF                                       Inferior to the right nipple             2.5         RR                          Radiotherapy and chemotherapy       \>36                                                         [@b11-ott-9-4969]
  6             F     42            Ankle               RR                48                            Back, buttock, brain, and right leg      Left upper outer                         2           LE                          Radiotherapy and chemotherapy       NA                                                           [@b12-ott-9-4969]
  7             F     39            Trunk               RR                36                            Brain, lung, and abdominal lymph nodes   Left medial quadrant                     1.4         LE                          Radiotherapy and chemotherapy       NA                                                           [@b13-ott-9-4969]
  8             M     62            Auricle             NA                96                            Groin, abdominal wall, and arm           Left upper outer                         4.5         RR                          NP                                  NA                                                           [@b14-ott-9-4969]
  9             M     50            Trunk               RR                2.5                           NF                                       Left lower inner                         0.8         RR                          NP                                  \>36                                                         [@b15-ott-9-4969]
  10            F     53            Foot                NA                24                            NF                                       Left and right                           NA          NA                          Chemotherapy                        8                                                            [@b16-ott-9-4969]
  11            F     70            NF                  NP                NA                            NF                                       Light upper                              8           RR                          NP                                  8                                                            [@b17-ott-9-4969]
  12            F     59            Anorectal           RR                4                             NF                                       Left upper outer                         4           RR                          NP                                  \>42                                                         [@b18-ott-9-4969]
  13            F     34            Finger              LE                3                             NF                                       Left and right                           1.5         Mastectomy                  NA                                  NA                                                           [@b19-ott-9-4969]
  14            F     34            Abdominal wall      NA                18                            NA                                       Right lower inner                        1           NA                          NA                                  NA                                                           [@b20-ott-9-4969]
  15            F     70            Eye, axilla         NA                12                            NA                                       Right upper outer                        2           NA                          NA                                  NA                                                           [@b20-ott-9-4969]
  16            F     53            Thigh               NA                72                            NA                                       Right upper outer                        0.8         NA                          NA                                  NA                                                           [@b20-ott-9-4969]
  17            F     45            Arm                 NA                NA                            NA                                       Left upper outer                         1           NA                          NA                                  NA                                                           [@b20-ott-9-4969]
  18            F     44            NF                  NA                108                           NA                                       Right upper outer                        3           NA                          NA                                  NA                                                           [@b20-ott-9-4969]
  19            M     56            NF                  NA                NA                            NA                                       Right lower outer                        NA          NA                          NA                                  NA                                                           [@b20-ott-9-4969]
  20            M     71            Back                NA                12                            NA                                       Left                                     3           NA                          NA                                  NA                                                           [@b20-ott-9-4969]
  21            F     60            Leg                 NA                178                           NA                                       Right upper outer                        NA          LE                          NA                                  14                                                           [@b21-ott-9-4969]
  22            F     84            Ankle               NA                13                            NA                                       Right upper outer                        NA          LE                          NA                                  14                                                           [@b21-ott-9-4969]
  23            F     48            Toe                 NA                25                            NA                                       Right medial upper                       NA          LE                          NA                                  10                                                           [@b21-ott-9-4969]
  24            F     68            Calf                NA                101                           NA                                       Right upper outer                        NA          LE                          NA                                  NA                                                           [@b21-ott-9-4969]
  25            F     47            Abdomen             NA                41                            NA                                       Right upper outer                        NA          RR                          NA                                  NA                                                           [@b21-ott-9-4969]
  26            F     58            Abdomen             NA                110                           NA                                       Left medial lower                        NA          NP                          NA                                  2                                                            [@b21-ott-9-4969]
  27            F     28            Temple              NA                72                            NA                                       Left medial lower                        NA          LE                          NA                                  NA                                                           [@b21-ott-9-4969]
  28            F     43            Scapula             NA                55                            NA                                       Left medial lower                        NA          LE                          NA                                  NA                                                           [@b21-ott-9-4969]
  29            F     40            Anorectal           RR                6                             NF                                       Left upper inner                         6           NP                          NP                                  \<1                                                          [@b22-ott-9-4969]
  30            F     59            Anorectal           RR                18                            NF                                       Right upper                              3           LE                          Chemotherapy                        \>12                                                         [@b23-ott-9-4969]
  31            F     55            Anorectal           NP                3                             Abdominal lymph nodes                    Left                                     1.5         NP                          NP                                  2.5                                                          [@b24-ott-9-4969]

**Abbreviations:** F, female; LE, local excision; M, male; NA, not available; NF, not found; NP, not performed; RR, radical resection.
